F. G. Good to discuss this point while the market is ignoring CSTs value. What other "aquisition" would make more sense? Perhaps buy another complimentary product line that can utilise our sales force to make them even more productive?
I would still like to get manufacture "in house" in the longer term. Does not stop having a contract manufacturer as a back-up. If Cellestis are going to expand their range of diagnostics using quantiferon technology then it will make sense to have R & D to scale-up, regulatory and production all in the one facility.
Gigarange - howmuch would Pharmasynth be worth? Any products / technology come with the deal?
Of course often Australian Companies that have a successful global product may want to aquire an offshore company if their are cost and logistical advantages in doing so.
CST Price at posting:
$2.00 Sentiment: Buy Disclosure: Held
